Veracyte

OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.

OncoCyte Corp0KCC · BiotechUnited States

70% matchPublic

Insight Molecular Diagnostics Inc., which transitioned from its former name OncoCyte Corporation in June 2025, functions as a specialized diagnostics enterprise with operations extending across the United States and internationally. The company's core activities involve pioneering and marketing a diverse array of diagnostic solutions, including laboratory developed tests, kitted products intended solely for research, and comprehensive kitted clinical tests. Its developmental pipeline features advanced tools such as DetermaCNI, a blood-based monitoring system engineered to identify early cancer progression promptly after just one treatment cycle. Another significant offering, DetermaIO, is a gene expression assay designed to evaluate the tumor microenvironment, thereby helping to predict a patient's potential response to immunotherapies. In the critical field of organ transplantation, Insight Molecular Diagnostics provides several vital monitoring products. Both VitaGraft Kidney and VitaGraft Liver are blood-based tests that precisely measure the concentration of donor-derived cell-free DNA (dd-cfDNA) to assess the status of kidney and liver transplants, respectively. Additionally, GraftAssure represents a sophisticated dd-cfDNA test that leverages droplet digital PCR (ddPCR) technology to quantify dd-cfDNA levels by examining 48 predefined single nucleotide polymorphisms (SNPs). Beyond its product offerings, the company delivers various specialized services, including biomarker discovery, comprehensive assay design and development, support for clinical trials, and a range of general biomarker testing. Furthermore, Insight Molecular Diagnostics maintains a strategic partnership with Bio-Rad Laboratories, Inc. This collaboration focuses on the advancement and commercialization of kitted transplant products for both research use only and in vitro diagnostics applications, utilizing Bio-Rad's proprietary ddPCR instruments and reagents. Founded in 2009, the company's headquarters are situated in Nashville, Tennessee.

Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

MDxHealth SA0O8G · BiotechHerstal, Belgium

68% matchPublic

MDxHealth SA is a commercial-stage precision diagnostics company specializing in urological solutions, with operations spanning the United States, the Netherlands, Belgium, Spain, Poland, Italy, the wider European Union, and various other international regions. The firm offers advanced genomic tests for prostate cancer, including SelectMDx, a non-invasive urine diagnostic, and ConfirmMDx, an epigenetic test. These innovative tools enable medical professionals to identify clinically significant prostate cancer while reducing the need for invasive procedures that carry potential complications. Incorporated in 2003, MDxHealth SA is headquartered in Herstal, Belgium, having changed its name from OncoMethylome Sciences SA in October 2010.

Resolution Bioscience is a precision medicine company specializing in cancer diagnostics, DNA sequencing, and liquid biopsy, located in Bellevue, Washington.